INTRODUCTION

Microglia are resident immune cells in the central nervous system that respond to extracellular stimuli and play a crucial role in host defense and tissue repair in brain [1,2]. However, aberrant activation of microglia has also been proposed to play a pathogenic role in neuro-inflammatory conditions such as ischemia, multiple sclerosis, Parkinson’s disease and Alzheimer’s disease [3-6]. Under these CNS disease conditions, activated microglia have been suggested to contribute to neurodegenerative process by producing pro-inflammatory mediators such as NO and several cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) [7-10]. Therefore, suppression of aberrant microglial activation may have valuable therapeutic potential for the treatment of inflammatory diseases in the CNS caused by activated microglia.

3,4,5-Trihydroxycinnamic acid (THC) is a derivative of hydroxycinnamic acids. Hydroxycinnamic acids have been reported to possess a wide variety of biological properties such as anti-inflammatory, anti-tumor, and neuroprotective activities [11-13]. Ester derivatives of hydroxycinnamic acids have been also reported to exhibit various biological activities [14]. Furthermore, it has been also reported that CAPE, caffeic acid phenylethyl ester, inhibits cytokine-mediated NF-κB activation in murine macrophage cells [15]. Although THC was previously identified in Rooibos tea (Aspalathus linearis) [16], its biological activity has not been extensively examined. Recently, it has been reported that THC inhibits human neutrophil elastase, which causes degradation of healthy tissues contributing to inflammatory diseases such as rheumatoid arthritis and psoriasis [11].

In the present study, in order to provide a novel pharmacological agent that could suppress abnormally activated microglia, the anti-inflammatory activity of THC, a derivative of hydroxycinnamic acids, has been properly examined. The objective of the present study is to evaluate the anti-inflammatory effects of THC on lipopolysaccharide (LPS)-stimulated BV2 microglial cells. THC significantly suppressed LPS-induced excessive production of nitric oxide (NO) and expression of iNOS, which is responsible for the production of iNOS. THC also suppressed LPS-induced overproduction of pro-inflammatory cytokines such as IL-1β and TNF-α in BV2 microglial cells. Furthermore, THC significantly suppressed LPS-induced degradation of IκB, which retains NF-κB in the cytoplasm. Therefore, THC attenuated nuclear translocation of NF-κB, a major pro-inflammatory transcription factor. Taken together, the present study for the first time demonstrates that THC exhibits anti-inflammatory activity through the suppression of NF-κB transcriptional activation in LPS-stimulated BV2 microglial cells.

Key Words: 3,4,5-Trihydroxycinnamic acid (THC), BV2 microglial cells, Lipopolysaccharide, iNOS, NF-κB

Received December 29, 2011, Revised March 28, 2012, Accepted April 3, 2012

Corresponding to: Wanjoo Chun, Department of Pharmacology, College of Medicine, Kangwon National University, Chuncheon 200-701, Korea. (Tel) 82-33-250-8853, (Fax) 82-33-255-8809, (E-mail) wchun@kangwon.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
METHODS

Reagents and cell culture

Bacterial lipopolysaccharide (LPS) from Escherichia coli serotype 055:B5 was purchased from Sigma-Aldrich (St. Louis, MO, USA). 3,4,5-Trihydroxycinnamic acid (THC) (Fig. 1) was purchased from APin Chemicals Limited (Abingdon, UK). The compound was solubilized in dimethyl sulfoxide (DMSO) and added to the cell culture at the desired concentrations. The BV2 microglial cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, Grand Island, NY, USA) containing 5% heat-inactivated fetal bovine serum (FBS; Gibco BRL) and 50 μg/ml gentamicin (Sigma, St. Louis, MO, USA) at 37°C, 5% CO2. In all experiments, cells were incubated in the presence of the indicated concentration of THC before the addition of LPS (200 ng/ml).

Cell viability

Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, cells (5×105) were seeded in 12 well plates and treated with various concentrations of THC for 24 hr. MTT (0.5 mg/ml in PBS) was added to each well, and the cells were incubated for 3 hr at 37°C and 5% CO2. The resulting formazan crystals were dissolved in dimethyl sulfoxide (DMSO). Absorbance was determined at 540 nm. The results were expressed as a percentage of surviving cells over control cells.

Nitrite quantification assay

The production of NO was estimated by measuring the amount of nitrite, a stable metabolite of NO, using the Griess reagent as described [14]. After THC-pretreated BV2 microglial cells were stimulated with LPS in 12-well plates for 24 hr, and then 100 μl of the cell culture media was added to each well. The cells were incubated for 3 hr at 37°C and 5% CO2. The resulting formazan crystals were dissolved in dimethyl sulfoxide (DMSO). Absorbance was determined at 540 nm. The results were expressed as a percentage of surviving cells over control cells.

**TNF-α and IL-1β ELISA**

The BV2 microglial cells were treated with THC in the absence or presence of LPS after 24 hr incubation, TNF-α and IL-1β levels in culture media were quantified using monoclonal anti-TNF-α or IL-1β antibodies according to the manufacturer’s instruction (R&D Systems).

Western blot analysis

The BV2 microglial cells were pretreated with THC for 1 hr and stimulated with LPS. Cells were washed with PBS and lysed with lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.02% sodium azide, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate, 1 mM phenyl methylsulfonyl fluoride). Equal amounts of protein were separated on 10% SDS-polycrylamide gel. Proteins were transferred to Hybond PVDF membrane (Amersham Biosciences, Piscataway, NJ, USA) and blocked in 5% skim milk in TBST for 1 hr at room temperature. Specific antibodies against inducible NO synthase (iNOS), IκB-α (1:1,000; Santa Cruz Biotechnology Inc) and β-actin (1:2,500; Sigma) were diluted in 5% skim milk. After thoroughly washing with TBST, horseradish peroxidase-conjugated secondary antibodies were applied. The blots were developed by the enhanced chemiluminescence detection (Amersham Biosciences).

**RNA isolation and Reverse transcription-polymerase chain reaction (RT-PCR)**

The BV2 microglial cells were treated with THC in the absence or presence of LPS for 6 h. Total RNA was isolated using the Total RNA Extraction Kit (iNtRON Biotechnology, Inc, USA) according to the manufacturer’s instruction. The total RNA (2 μg) obtained from cells was reverse-transcribed using oligo-(dT) 15 primers (Promega, Madison, WI, USA). PCR amplification conditions using primer sets specific for iNOS, TNF-α, IL-1β and β-actin were optimized for each pair of primers. PCR primers were as follows: mouse iNOS forward, 5’-CCCTTC CGAAGTTTCTGGC-AGCAG C-3’; iNOS reverse, 5’-GGCGTGTCAAGGCTGGTTG-TGCTTGGTG G-3’; TNF-α forward, 5’-CATTCCTTCATAAAATTCGAGTGACAA-3’; TNF-α reverse, 5’-ACCTGGG AGATGACTTCA G-3’; IL-1β forward, 5’-GCAAATTTCTCAGCTGAACTC-3’; IL-1β reverse, 5’-CCCTGGGAGCCTGTAGTGGCA T-3’; β-actin forward, 5’-ATCCCTGAAACACCTTATGC-3’; β-actin reverse, 5’-AAGCCAGCTGACATGACT-3’. Parallel PCR analysis was run for the house keeping gene β-actin to normalize data for differences in mRNA quantity and integrity. PCR products were separated on agarose gel.

**Immunofluorescence assay**

The BV2 microglial cells were cultured in sterile coverslips and pretreated with THC for 1 hr and stimulated with LPS. After 30 min, the cells were fixed in 4% paraformaldehyde for 20 min at room temperature. The fixed cells were then permeabilized with 0.1% Triton X-100 in PBS and blocked with 3% BSA. Afterwards, the cells were sequentially incubated with rabbit anti-p65 antibody (1:100; Santa Cruz Biotechnology Inc) at room temperature and Alexa 546-labeled goat anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) at room temperature for 1 hr. Cells were washed with PBS, and then stained with 0.5 μg/ml of Hoechst staining solution for 10 min at room temperature. After washing with PBS, the coverslips were mounted and observed by confocal microscopy.

**Fig. 1.** Chemical structure of 3,4,5-Trihydroxycinnamic acid (THC).
Anti-Inflammatory Effects of 3,4,5-Trihydroxycinnamic Acid

Fig. 2. THC inhibited NO production (A) and expression levels of iNOS protein (B) and mRNA (C) in LPS-stimulated BV2 microglial cells. (A) BV2 cells were pretreated with various concentrations of THC (0, 0.1, 1, 10, 25, 50 or 100 μM) for 1 hr prior to LPS treatment and Griess reaction was used as an index for NO synthesis. As shown in Fig. 2A, LPS markedly increased NO production in BV2 microglial cells. However, THC significantly inhibited NO production in LPS-stimulated BV2 microglial cells in a concentration dependent manner (Fig. 2A). In addition, THC showed no significant cytotoxicity in concentration ranges, in which THC exhibits suppressive activity of NO production, irrespective of LPS presence (data not shown).

THC inhibits LPS-induced mRNA and protein expression of iNOS

As THC was found to inhibit NO production in Fig. 2A, we examined the mRNA and protein expression levels of iNOS upon THC treatment, using RT-PCR and Western blot analyses, respectively. LPS resulted in markedly increased expression of iNOS protein, which was significantly suppressed with THC treatment in a concentration-dependent manner (Fig. 2B). Consistent with the decrease of iNOS protein, THC also significantly attenuated LPS-induced up-regulation of iNOS mRNA expression (Fig. 2C). These results demonstrate that THC possesses significant inhibitory effects on LPS-induced expression of iNOS, which is considered as a major source of cytotoxic NO.

RESULTS

THC suppresses NO production in LPS-stimulated BV2 microglial cells

Based on that NO production has been widely used as a representative measure of inflammatory activation of microglia [17], we measured suppressive effects of THC on NO production in LPS-stimulated BV2 microglial cells. Cells were incubated with indicated concentrations of THC (0, 0.1, 1, 10, 25, 50 or 100 μM) for 1 hr prior to LPS treatment and Griess reaction was used as an internal control for NO synthesis. As shown in Fig. 2A, LPS markedly increased NO production in BV2 microglial cells. However, THC significantly inhibited NO production in LPS-stimulated BV2 microglial cells in a concentration dependent manner (Fig. 2A). In addition, THC showed no significant cytotoxicity in concentration ranges, in which THC exhibits suppressive activity of NO production, irrespective of LPS presence (data not shown).

THC inhibits LPS-induced mRNA and protein expression of iNOS

As THC was found to inhibit NO production in Fig. 2A, we examined the mRNA and protein expression levels of iNOS upon THC treatment, using RT-PCR and Western blot analyses, respectively. LPS resulted in markedly increased expression of iNOS protein, which was significantly suppressed with THC treatment in a concentration-dependent manner (Fig. 2B). Consistent with the decrease of iNOS protein, THC also significantly attenuated LPS-induced up-regulation of iNOS mRNA expression (Fig. 2C). These results demonstrate that THC possesses significant inhibitory effects on LPS-induced expression of iNOS, which is considered as a major source of cytotoxic NO.

THC attenuates LPS-induced gene expression and release of pro-inflammatory cytokines

To examine the effects of THC on TNF-α and IL-1β gene expression at the transcriptional level, RT-PCR was performed in the LPS-stimulated BV2 microglial cells. THC significantly suppressed LPS-induced expression of these genes in a concentration-dependent manner (Fig. 3A). In accordance with the change in gene expression of cytokines, THC resulted in a significant suppression of LPS-induced extracellular release of these cytokines (Fig. 3B).

THC attenuates nuclear translocation of NF-κB via suppression of LPS-induced IκB degradation

Given the previous report that the transcription factor NF-κB is a predominant regulator of iNOS and numerous pro-inflammatory genes [17,18] and that IκB inhibits the nuclear translocation of p65 subunit of NF-κB, we investigated whether THC inhibits LPS-induced nuclear translocation of NF-κB and degradation of cytosolic IκB. THC blocked LPS-induced degradation of IκB in a concentration-dependent manner (Fig. 4). The cellular localization of p65 was investigated by immunofluorescence staining.
Fig. 3. THC inhibited gene expression (A) and release (B) of TNF-α and IL-1β in LPS-stimulated BV2 microglial cells. (A) BV2 microglia cells were pretreated with the indicated concentrations of THC for 1 hr before LPS treatment (200 ng/ml), and total RNA was isolated at 6 hr after LPS treatment and mRNA levels were determined by RT-PCR analysis. THC significantly suppressed expression of TNF-α and IL-1β. Data from triplicate determination are shown (mean±SD). (B) Cell culture media were collected and subjected to TNF-α and IL-1β ELISA. Data represent three independent experiments in triplicate and are expressed as mean±SD. *p<0.05 and **p<0.01 indicate statistically significant differences from treatment with LPS alone. ##p<0.01 indicates statistically significant differences between indicated groups.

Fig. 4. Inhibitory effects of THC on LPS-induced IκB-α degradation in BV2 microglial cells. Total cell lysates obtained 15 min after the LPS stimulation were subjected to Western blotting to assess the levels of IκB-α degradation (top). Quantification of IκB-α degradation was performed by densitometric analysis (lower). The β-actin was used as an internal control. Data from triplicate determination are shown (mean±S.D.). *p<0.05 and **p<0.01 indicate statistically significant differences from treatment with LPS alone.

Fig. 5. THC suppressed the nuclear localization of NF-κB in LPS-stimulated BV2 microglial cells. (A) BV2 microglia cells were pretreated with THC for 1 hr prior to stimulation with 200 ng/ml LPS for 1 hr. Localization of NF-κB p65 subunit was determined using an anti-p65 antibody and an Alexa 546-labeled goat anti-rabbit IgG antibody. Nuclei were visualized by Hoechst staining. Cells were visualized using confocal scanning microscopy. Scale bar=20 μm. (B) NF-κB localization was further examined by line scanning. These results clearly indicate that THC suppresses LPS-induced NF-κB activation in BV2 microglial cells.
**DISCUSSION**

The present study clearly demonstrated that THC exhibits anti-inflammatory activity in LPS-stimulated BV2 microglial cells. THC significantly suppressed LPS-induced production of NO, upregulation of iNOS expression, and release of pro-inflammatory cytokines such as TNF-α and IL-1β. Furthermore, THC significantly attenuated LPS-induced iNOS degradation and consequent nuclear translocation of NF-κB, a pro-inflammatory transcription factor.

Phenylpropanoids are a group of plant-derived secondary metabolites that are biosynthesized from phenylalanine to coumaric acid and other acids including caffeic acid, ferulic acid, and trihydroxycinnamic acid. Hydroxycinnamic acids and their ester derivatives have been reported to possess a broad spectrum of pharmacological activities including antitumor, antiviral, anti-inflammatory, immunosuppressive, and neuroprotective activities [12-14]. Although it has been, recently, reported that chemically synthesized THC exerts inhibitory activity against human neutrophil elastase, which is involved in the regulation of inflammatory processes [11], the biological properties of THC have not been compared to those of other hydroxycinnamic acids. In the present study, anti-inflammatory activities of THC, originally present in Aspalathus linearis [16], was examined in comparison with caffeic acid, a prototype hydroxycinnamic acid. Both THC and caffeic acid showed significant suppression of LPS-induced NO production in BV2 microglial cells (Fig. 2A). However, THC exhibited significantly greater suppression on LPS-induced NO production compared to caffeic acid. Furthermore, THC showed suppression in a concentration-dependent manner.

Aberrant activation of microglia has been reported to contribute to neuronal damage in several pathologic conditions by releasing pro-inflammatory mediators such as TNF-α, IL-1β and NO [19,20]. Accordingly, suppression of microglial activation and subsequent release of cytokines have been demonstrated to protect neuronal damage in several inflammation-related CNS diseases [3,21,22]. The present study clearly showed that THC suppresses LPS-induced expression of TNF-α and IL-1β and their extracellular release. However, effects of THC on other pro-inflammatory cytokines have not been examined. Therefore, further studies are necessary to examine the effect of THC on the release and gene expression of other cytokines. In addition, the present study showed that THC significantly suppressed LPS-induced NO production, a well-known pro-inflammatory mediator, through the suppression of iNOS gene expression. NF-κB is an important transcription factor for pro-inflammatory mediators such as iNOS, IL-1β and TNF-α [23,24] and inappropriate regulation of NF-κB and its downstream genes have been associated with various pathological conditions including cancer and autoimmune diseases [25,26]. It has been reported that LPS causes the nuclear translocation of p65 subunit of NF-κB through IκB degradation [27,28]. In accordance with these reports, the present study showed that THC significantly attenuated LPS-induced IκB degradation and consequent nuclear translocation of p65 in LPS-induced BV2 microglial cells (Fig. 5A).

In conclusion, the results clearly demonstrate that THC possesses anti-inflammatory activity such as suppression of NO production and cytokine release by inhibiting nuclear translocation of NF-κB in LPS-stimulated BV2 microglial cells. The present study strongly suggests that THC might be a valuable therapeutic agent in the treatment of inflammation-related brain pathologies such as ischemia and neurodegenerative diseases. Due to the lack of reports on THC, although no noticeable cytotoxic property of THC was observed in the concentration ranges used in the present study, further studies are necessary to extensively detect any possible toxicities of THC. This endeavor could enhance the possibility of THC for therapeutic application.

**REFERENCES**

1. Sugama S. Stress-induced microglial activation may facilitate the progression of neurodegenerative disorders. *Med Hypotheses*. 2009;73:1031-1034.
2. Perry VH, Gordon S. Macrophages and microglia in the nervous system. *Trends Neurosci*. 1998;21:273-277.
3. Hailer NP. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illustrates the role of microglial cells. *Prog Neurobiol*. 2008;84:211-233.
4. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. *J Neuroimmunol*. 1989;24:173-182.
5. Matsumoto H. Some markers reflecting the pathology and disease activity of multiple sclerosis. *No To Shinkei*. 1992;44:95-102.
6. McGeer PL, McGeer EG. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. *Alzheimer Dis Assoc Disord*. 1998;12 Suppl 2:S1-6.
7. Tuttolomondo A, Di Raimondo D, di Silvestra R, Pinto A, Licitra G. Inflammatory cytokines in acute ischemic stroke. *Curr Pharm Des*. 2008;14:3574-3589.
8. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. *Trends Neurosci*. 1996;19:331-338.
9. Chao CC, Hu S, Close K, Choi CS, Moltitor TW, Novick WJ, Peterson PK. Cytokine release from microglia: differential inhibition by pentoxifylline and dexamethasone. *J Infect Dis*. 1992;166:847-853.
10. Lee IS, Lim J, Gal J, Kang JC, Kim HJ, Kang BY, Choi HJ. Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. *Neurochem Int*. 2011;58:153-160.
11. Steinbrecher T, Hrenn A, Dormann KL, Merfort I, Labahn A. Bornyl (3,4,5-trihydroxy)-cinnamate—an optimized human neutrophil elastase inhibitor designed by free energy calculations. *Bioorg Med Chem*. 2008;16:2385-2390.
12. Nagasaka R, Chotimarkorn C, Shafiquil IM, Hori M, Ozaki H, Ushio H. Anti-inflammatory effects of hydroxycinnamic acid derivatives. *Biochem Biophys Res Commun*. 2007;358:615-619.
13. Kim YC. Neuroprotective phenolics in medicinal plants. *Arch Pharm Res*. 2010;33:1611-1632.
14. Lee JW, Cheong HY, Kim HS, Lee JJ, Lee YS, Kwon YS, Kim MJ, Lee HJ, Kim SS, Chun W. Anti-inflammatory activity of 1-docosanoyl cafferate isolated from rhus verniciflua in LPS-stimulated BV2 microglial cells. *Korean J Physiol Pharmacol*. 2011;15:9-15.
15. Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, Kwak JK. Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. *Eur J Pharmacol*. 2010;643:21-28.
16. Rabe C, Steenkamp JA, Joubert E, Burger JF, Ferreira D. Phenolic metabolites from rhoobus tea (Aspalathus linearis). *Phytochem*. 1994;35:1559-1565.
17. Ock J, Kim S, Suk K. Anti-inflammatory effects of a fluoroxyloxyacetamide compound KT-15087 in microglia cells. *Pharmacol Res*. 2009;59:414-422.
18. Zheng LT, Ryu GM, Kwon BM, Lee WH, Suk K. Anti-inflammatory effects of catechols in lipopolysaccharide-sti-
mulated microglia cells: inhibition of microglial neurotoxicity. 
*Eur J Pharmacol.* 2008;588:106-113.

19. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. *Trends Neurosci.* 1996;19:312-318.

20. Graeber MB, Streit WJ. Microglia: biology and pathology. *Acta Neuropathol.* 2010;119:89-105.

21. Aquilano K, Baldelli S, Rotilio G, Cirio MR. Role of nitric oxide synthases in Parkinson’s disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. *Acta Neuropathol.* 2010;119:89-105.

22. Ray B, Lahiri DK. Neuroinflammation in Alzheimer’s disease: different molecular targets and potential therapeutic agents including curcumin. *Curr Opin Pharmacol.* 2009;9:434-444.

23. Kuprash DV, Udalova IA, Turetskaya RL, Rice NR, Nedospasov SA. Conserved kappa B element located downstream of the tumor necrosis factor alpha gene: distinct NF-kappa B binding pattern and enhancer activity in LPS activated murine macrophages. *Oncogene.* 1995;11:97-106.

24. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. *Annu Rev Cell Biol.* 1994;10:405-455.

25. Li Q, Verna IM. NF-kappaB regulation in the immune system. *Nat Rev Immunol.* 2002;2:725-734.

26. Karin M, Takahashi T, Kappah P, Delhase M, Chen Y, Makris C, Rothwarf D, Baud V, Natoli G, Guido F, Li N. Oxidative stress and gene expression: the AP-1 and NF-kappaB connections. *Biofactors.* 2001;15:87-89.

27. Moon DO, Park SY, Lee KJ, Heo MS, Kim KC, Kim MO, Lee JD, Choi VH, Kim GY. Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia. *Int Immunopharmacol.* 2007;7:1092-1101.

28. Zheng LT, Ock J, Kwon BM, Suk K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. *Int Immunopharmacol.* 2008;8:484-494.